Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
